Full Body Cancer Screening: MRI vs Blood Tests vs Genetic Testing

Cancer is the second leading cause of death in the UK, with approximately 375,000 new cases diagnosed each year (Cancer Research UK, 2023). Early detection dramatically improves survival — for many cancers, 5-year survival exceeds 90% at stage 1 but drops below 20% at stage 4. This guide compares the three main approaches to full body cancer screening: MRI, blood tests, and genetic testing.

The Three Approaches to Cancer Screening

1. MRI Scanning

MRI uses magnetic fields to create detailed images of organs and tissues. A full body MRI can detect solid tumours in the brain, spine, chest, abdomen, pelvis, and bones. Diffusion-weighted whole-body imaging (DWIBS/DWI) is a protocol specifically designed for cancer screening — it highlights areas of abnormal cellular density that may indicate malignancy.

Strengths

• Detects tumours as small as 5mm in many body areas
• No ionising radiation — safe for repeated annual or biennial screening
• Shows tumour location, size, and relationship to surrounding structures
• Covers brain, solid organs, bones, and lymph nodes in a single scan (60-90 minutes)
• Can often distinguish benign from potentially malignant lesions based on signal characteristics

Limitations

• Poor at detecting lung cancer (low water content in lungs; CT is far better)
• Can't reliably detect very early mucosal cancers (oesophageal, gastric, bladder)
• High rate of incidental findings (~40% of healthy adults will have at least one finding needing follow-up)
• Expensive (from £1,399 for full body through Lola Health)
• Not available on the NHS as a routine screening tool

2. Blood Tests (Liquid Biopsy and Tumour Markers)

Blood-based screening is evolving rapidly. Two main categories:

Traditional Tumour Markers

• PSA (Prostate-Specific Antigen) — Screens for prostate cancer in men. Elevated PSA triggers further investigation (usually prostate MRI). Sensitivity and specificity are imperfect — PSA can be elevated by benign conditions (BPH, prostatitis, recent exercise). But it remains the most established blood-based cancer screening test.
• CA125 — Ovarian cancer marker. Can be elevated by endometriosis, fibroids, and other benign conditions. Used alongside ultrasound and family history for risk assessment.
• CEA — Colorectal cancer marker. More useful for monitoring known cancer than for screening healthy people.
• AFP — Liver cancer marker. Useful for screening high-risk individuals (hepatitis B/C carriers, cirrhosis patients).

Multi-Cancer Early Detection Tests (Liquid Biopsy)

These are blood tests that look for circulating tumour DNA (ctDNA) or other cancer signals shed by tumours into the bloodstream. The most publicised is Grail's Galleri test, which screens for over 50 cancer types from a single blood draw. Clinical evidence (the PATHFINDER study, 2022) showed a positive predictive value of ~44%, meaning roughly half of positive results confirmed cancer. The technology is promising but still maturing — sensitivity for early-stage cancers remains limited, and false negatives are common.

Strengths of Blood Tests

• Quick and non-invasive (a simple blood draw)
• Can detect some cancers that MRI misses (e.g., blood cancers, some mucosal cancers)
• Cheaper than MRI (individual markers £50-£100; multi-cancer tests £500-£1,000)
• Rapidly improving technology

Limitations of Blood Tests

• Can't show tumour location, size, or extent (you'd still need imaging for that)
• False positives and false negatives are real issues
• Traditional tumour markers have poor specificity when used for population screening
• Multi-cancer tests are still in early clinical validation

3. Genetic Testing

Genetic testing identifies inherited mutations that significantly increase cancer risk:

• BRCA1/BRCA2 — Breast cancer risk increases to 45-72% (vs 12% population average); ovarian cancer risk to 10-44% (NICE CG164).
• Lynch syndrome (MLH1, MSH2, MSH6, PMS2) — Colorectal cancer risk up to 80%; endometrial cancer risk up to 60%.
• Li-Fraumeni syndrome (TP53) — Multiple cancer types, often at young ages.
• APC gene mutations — Familial adenomatous polyposis (near-100% colorectal cancer risk without intervention).

Strengths

• Test once, results are permanent
• Identifies people who need intensified surveillance before cancer develops
• Can trigger access to NHS high-risk screening pathways (e.g., annual MRI for BRCA carriers)
• Enables risk-reducing interventions (prophylactic surgery, enhanced surveillance)

Limitations

• Only detects hereditary cancer risk (~5-10% of all cancers)
• Can't detect cancer itself — only increased susceptibility
• Psychological impact of knowing you carry a high-risk mutation
• Many cancers occur in people with no identifiable genetic risk

The Ideal Approach: Use All Three Together

No single screening method catches everything. The strongest approach combines all three:

1. Genetic testing — Identifies your baseline inherited risk (do this once).
2. Blood tests — Annual screening for biochemical signals (tumour markers, inflammatory markers, organ function).
3. MRI — Structural imaging every 1-3 years (full body or targeted to your highest-risk areas based on genetics and history).
4. NHS screening — Continue participating in bowel, breast, and cervical programmes as offered.

Frequently Asked Questions

Which is best for cancer screening — MRI, blood tests, or genetic testing?

They answer different questions. Genetic testing tells you your inherited risk. Blood tests detect biochemical signals. MRI finds physical tumours. Using all three together gives you the most complete picture. None alone is sufficient.

Can a full body MRI find all cancers?

No. MRI is excellent for solid tumours in the brain, abdomen, pelvis, and bones, but poor for lung cancer (CT is better) and limited for very early mucosal cancers. Blood cancers (leukaemia, lymphoma) may show as lymphadenopathy on MRI but are primarily detected through blood tests.

Should I have an annual full body MRI?

It depends on your risk profile. For high-risk individuals (strong family history, known genetic mutations), annual screening is reasonable. For average-risk adults, every 2-3 years after an initial baseline is a practical approach. See our guide on how often to get an MRI.

Is cancer screening available on the NHS?

NHS cancer screening covers bowel (FIT test, age 56-74), breast (mammography, age 50-70), and cervical (HPV test, age 25-64). Full body MRI screening, multi-cancer blood tests, and genetic testing for cancer risk are available privately.